205 related articles for article (PubMed ID: 27599396)
1. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
3. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
4. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
Hagiwara M; Kikuchi E; Kosaka T; Mikami S; Saya H; Oya M
Urol Oncol; 2016 Aug; 34(8):337.e19-26. PubMed ID: 27133224
[TBL] [Abstract][Full Text] [Related]
5. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
Wu CT; Lin WY; Chen WC; Chen MF
Ann Surg Oncol; 2018 Nov; 25(12):3518-3526. PubMed ID: 30128900
[TBL] [Abstract][Full Text] [Related]
6. Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer.
Mashita N; Yamada S; Nakayama G; Tanaka C; Iwata N; Kanda M; Kobayashi D; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Kodera Y
J Surg Oncol; 2014 Nov; 110(6):745-51. PubMed ID: 24975268
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characterisation of duodenal adenocarcinoma with high CD44 variant 9 expression.
Maruyama Y; Uehara T; Daikuhara S; Kobayashi Y; Nakajima T; Matsumoto A; Tanaka E; Ota H
Pathology; 2015 Dec; 47(7):647-52. PubMed ID: 26517627
[TBL] [Abstract][Full Text] [Related]
8. CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence.
Suenaga M; Yamada S; Fuchs BC; Fujii T; Kanda M; Tanaka C; Kobayashi D; Fujiwara M; Tanabe KK; Kodera Y
J Surg Oncol; 2015 Nov; 112(6):622-8. PubMed ID: 26416034
[TBL] [Abstract][Full Text] [Related]
9. CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues.
Yamakawa Y; Kusuhara M; Terashima M; Kinugasa Y; Sugino T; Abe M; Mochizuki T; Hatakeyama K; Kami K; Yamaguchi K
Biomed Res; 2017; 38(1):41-52. PubMed ID: 28239031
[TBL] [Abstract][Full Text] [Related]
10. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development.
Wu K; Zeng J; Zhou J; Fan J; Chen Y; Wang Z; Zhang T; Wang X; He D
Urol Oncol; 2013 Nov; 31(8):1751-60. PubMed ID: 22421353
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer.
Katoh S; Goi T; Naruse T; Ueda Y; Kurebayashi H; Nakazawa T; Kimura Y; Hirono Y; Yamaguchi A
Anticancer Res; 2015 Jan; 35(1):239-44. PubMed ID: 25550556
[TBL] [Abstract][Full Text] [Related]
12. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
13. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M
Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044
[TBL] [Abstract][Full Text] [Related]
15. Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer.
Aso T; Matsuo M; Kiyohara H; Taguchi K; Rikimaru F; Shimokawa M; Segawa Y; Higaki Y; Umeno H; Nakashima T; Masuda M
PLoS One; 2015; 10(3):e0116596. PubMed ID: 25751671
[TBL] [Abstract][Full Text] [Related]
16. CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma.
Taniguchi D; Saeki H; Nakashima Y; Kudou K; Nakanishi R; Kubo N; Ando K; Oki E; Oda Y; Maehara Y
Cancer Med; 2018 Dec; 7(12):6258-6268. PubMed ID: 30474922
[TBL] [Abstract][Full Text] [Related]
17. Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20.
Al-Sharaky DR; Abdelwahed M; Asaad N; Foda A; Abdou AG
J Immunoassay Immunochem; 2021 May; 42(3):236-251. PubMed ID: 33213275
[TBL] [Abstract][Full Text] [Related]
18. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
[TBL] [Abstract][Full Text] [Related]
19. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
Hagiwara M; Kikuchi E; Tanaka N; Kosaka T; Mikami S; Saya H; Oya M
BMC Cancer; 2018 Jan; 18(1):113. PubMed ID: 29385995
[TBL] [Abstract][Full Text] [Related]
20. CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells.
Van Driel M; Günthert U; van Kessel AC; Joling P; Stauder R; Lokhorst HM; Bloem AC
Leukemia; 2002 Jan; 16(1):135-43. PubMed ID: 11840273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
